Stock IF0 INFLARX N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases InflaRx N.V. Xetra

Equities

IF0

NL0012661870

End-of-day quote Xetra
Other stock markets
 23:00:00 18/08/2022 BST 		5-day change 1st Jan Change
2.939 EUR -.--% Intraday chart for InflaRx N.V. -.--% -.--%
06-24 Sector Update: Health Care Stocks Advance Monday Afternoon MT
06-24 Sector Update: Health Care MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
InflaRx N : SALES AGREEMENT Form 6 K
PU
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
AQ
InflaRx Hosts R&D Event Highlighting the Promise of INF904
AQ
InflaRx N : INF904 R&D Event
PU
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
AQ
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
AQ
InflaRx N : 20240425_Minutes 2024 AGM - InflaRx NV_signed
PU
InflaRx N : Deed of Amendment to the Articles of Association, dated April 25, 2024 - Form 6-K
PU
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
AQ
InflaRx N : News Conference Call March 2024
PU
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
AQ
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
AQ
InflaRx Appoints Jan Medina as Head of Investor Relations
AQ
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
GL
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
AQ
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
AQ
InflaRx N : 11-2023-InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
PU
INFLARX N : UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – SEPTEMBER 30, 2023 - Form 6-K
PU
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IFRX Stock
  4. IF0 Stock
  5. News InflaRx N.V.
  6. Press Releases